The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis

Cellular Oncology

Volumn 32, Issue 4, 2010, Pages 285-300

  Di Fazio, Pietro ^a,b,f   Schneider Stock, Regine ^a   Neureiter, Daniel ^c   Okamoto, Kinya ^a,d   Wissniowski, Till ^a   Gahr, Susanne ^a   Quint, Karl ^a,f   Meissnitzer, Matthias ^c   Alinger, Beate ^c   Montalbano, Roberta ^b,f   Sass, Gabriele ^e   Hohenstein, Bernd ^a   Hahn, Eckhart G ^a   Ocker, Matthias ^a,f  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF PALERMO   (Italy)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d TOTTORI UNIVERSITY   (Japan)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Caspase 12; Endoplasmic reticulum stress; HDAC; LBH589; P21cip1 waf1; Transcriptional regulation; Unfolded protein response (UPR); Xenograft model

Indexed keywords

CASPASE 12; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HISTONE H2AX; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; PANOBINOSTAT; PROTEIN P21; PROTEIN P53;

ACETYLATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUALITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FIBROBLASTS; HEP G2 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; TRANSCRIPTION FACTOR CHOP; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; UNFOLDED PROTEIN RESPONSE;

EID: 77953373245     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2010-0511     Document Type: Article

References (47)

1. G.K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. San-toro, A. Figer, J. De Greve, J.Y. Douillard, C. Lathia, B. Schwartz,I. Taylor, M. Moscovici, L.B. Saltz, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J. Clin. Oncol. 24, 2006. 4293-4300.
2. P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto and K. Bhalla, Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors, J. Biol. Chem. 280 (2005), 26729-26734.
3. R.C. Bleackley and J.A. Heibein, Enzymatic control of apop-tosis, Nat. Prod. Rep. 18 (2001), 431-440.
4. T. Bluethner, M. Niederhagen, K. Caca, F. Serr, H. Witzig-mann, C. Moebius, J. Mossner and M. Wiedmann, Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach, World J. Gastroenterol. 13 (2007), 4761-4770.
5. L.M. Butler, V. Liapis, S. Bouralexis, K. Welldon, S. Hay, M. Thai le, A. Labrinidis, W.D. Tilley, D.M. Findlay and A. Evdokiou, The histone deacetylase inhibitor, suberoy-lanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL, Int. J. Cancer 119 (2006), 944-954.
6. S. Chang, B.D. Young, S. Li, X. Qi, J.A. Richardson and E.N. Olson, Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10, Cell 126 (2006), 321-334.
7. J. Chen, W. Fiskus, K. Eaton, P. Fernandez, Y. Wang, R. Rao, P. Lee, R. Joshi, Y. Yang, R. Kolhe, R. Balusu, P. Chappa, K. Natarajan, A. Jillella, P. Atadja and K.N. Bhalla, Cotreatment with BCL-2 antagonist sensitizes cutaneous T cell lymphoma to lethal action of HDAC7-Nur77 based mechanism, Blood 113 (2009), 4038-4048.
8. E.L. Davenport, H.E. Moore, A.S. Dunlop, S.Y. Sharp, P. Workman, G.J. Morgan and F.E. Davies, Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells, Blood 110 (2007), 2641-2649.
9. M. Duvic and J. Vu, Vorinostat: a new oral histone deacety-lase inhibitor approved for cutaneous T-cell lymphoma, Expert Opin. Investig. Drugs 16 (2007), 1111-1120.
10. A. Edwards, J. Li, P. Atadja, K. Bhalla and E.B. Haura, Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells, Mol. Cancer Ther. 6 (2007), 2515-2524.
11. H.B. El-Serag and K.L. Rudolph, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology 132 (2007), 2557-2576.
12. S. Emanuele, M. Lauricella, D. Carlisi, B. Vassallo, A. D'Anneo, P. Di Fazio, R. Vento and G. Tesoriere, SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib, Apoptosis 12 (2007), 1327-1338.
13. W. Fiskus, Y. Ren, A. Mohapatra, P. Bali, A. Mandawat, R. Rao, B. Herger, Y. Yang, P. Atadja, J. Wu and K. Bhalla, Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90, Clin. Cancer Res. 13 (2007), 4882-4890.
14. P. George, P. Bali, S. Annavarapu, A. Scuto, W. Fiskus, F. Guo, C. Sigua, G. Sondarva, L. Moscinski, P. Atadja and K. Bhalla, Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of F LT-3, Blood 105 (2005), 1768-1776.
15. F. Giles, T. Fischer, J. Cortes, G. Garcia-Manero, J. Beck, F. Ravandi, E. Masson, P. Rae, G. Laird, S. Sharma, H. Kantar-jian, M. Dugan, M. Albitar and K. Bhalla, A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies, Clin. Cancer Res. 12 (2006), 4628-4635.
16. C. Habold, A. Poehlmann, K. Bajbouj, R. Hartig, K.S. Ko-rkmaz, A. Roessner and R. Schneider-Stock, Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis, J. Cell. Mol. Med. 12 (2008), 607-621.
17. R. Hallmann, D.N. Mayer, E.L. Berg, R. Broermann and E.C. Butcher, Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier, Dev. Dyn. 202 (1995), 325-332.
18. C. Herold, M. Ganslmayer, M. Ocker, M. Hermann, A. Geerts, E.G. Hahn and D. Schuppan, The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells, J. Hepatol. 36 (2002), 233-240.
19. C.L. Hirsch and K. Bonham, Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells, FEBS Lett. 570 (2004), 37-40.
20. K.K. Khanna and S.P. Jackson, DNA double-strand breaks: signaling, repair and the cancer connection, Nat. Genet. 27 (2001), 247-254.
21. R. Kim, M. Emi, K. Tanabe and S. Murakami, Role of the unfolded protein response in cell death, Apoptosis 11 (2006), 5-13. (Pubitemid 43151639)
22. M. Lamkanfi, N. Festjens, W. Declercq, T. Vanden Berghe and P. Vandenabeele, Caspases in cell survival, proliferation and differentiation, Cell Death Differ. 14 (2007), 44-55.
23. P. Maiso, X. Carvajal-Vergara, E.M. Ocio, R. Lopez-Perez, G. Mateo, N. Gutierrez, P. Atadja, A. Pandiella and J.F. San Miguel, The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance, Cancer Res. 66 (2006), 5781-5789.
24. M.G. Marcu, M. Doyle, A. Bertolotti, D. Ron, L. Hendershot and L. Neckers, Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha, Mol. Cell. Biol. 22 (2002), 8506-8513.
25. T. Momoi, Caspases involved in ER stress-mediated cell death, J. Chem. Neuroanat. 28 (2004), 101-105.
26. D. Mottet, A. Bellahcene, S. Pirotte, D. Waltregny, C. Deroanne, V. Lamour, R. Lidereau and V. Castronovo, His-tone deacetylase 7 silencing alters endothelial cell migration, key step in angiogenesis, Circ. Res. 101 (2007), 1237-1246.
27. D. Neureiter, S. Zopf, T. Leu, O. Dietze, C. Hauser-Kronberger, E.G. Hahn, C. Herold and M. Ocker, Apoptosis, proliferation and differentiation patterns are influenced by Ze-bularine and SAHA in pancreatic cancer models, Scand. J. Gastroenterol. 42 (2007), 103-116.
28. M. Ocker, A. Alajati, M. Ganslmayer, S. Zopf, M. Luders, D. Neureiter, E.G. Hahn, D. Schuppan and C. Herold, The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells, J. Cancer Res. Clin. Oncol. 131 (2005), 385-394.
29. M. Ocker and R. Schneider-Stock, Histone deacetylase inhibitors: signalling towards p21cip1/waf1, Int. J. Biochem. Cell Biol. 39 (2007), 1367-1374.
30. K. Okamoto, D. Neureiter and M. Ocker, Biomarkers for novel targeted therapies of hepatocellular carcinoma, Histol. Histopathol. 24 (2009), 493-502.
31. S. Oyadomari and M. Mori, Roles of CHOP/GADD153 in en-doplasmic reticulum stress, Cell Death Differ. 11 (2004), 381-389.
32. A. Pathil, S. Armeanu, S. Venturelli, P. Mascagni, T.S. Weiss, M. Gregor, U.M. Lauer and M. Bitzer, HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL, Hepatology 43 (2006), 425-434.
33. T.T. Paull, E.P. Rogakou, V. Yamazaki, C.U. Kirchgessner, M. Gellert and W.M. Bonner, A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage, Curr. Biol. 10 (2000), 886-895.
34. D.Z. Qian, Y. Kato, S. Shabbeer, Y. Wei, H.M. Verheul, B. Salumbides, T. Sanni, P. Atadja and R. Pili, Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydrox-amic acid derivative LBH589, Clin. Cancer Res. 12 (2006), 634-642.
35. R.V. Rao, S. Castro-Obregon, H. Frankowski, M. Schuler, V. Stoka, G. del Rio, D.E. Bredesen and H.M. Ellerby, Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway, J. Biol. Chem. 277 (2002), 21836-21842. (Pubitemid 34952336)
36. M.A. Robbins, L. Maksumova, E. Pocock and J.K. Chantler, Nuclear factor-kappaB translocation mediates double-stranded ribonucleic acid-induced NIT-1 beta-cell apoptosis and up-regulates caspase-12 and tumor necrosis factor receptor-associated ligand (TRAIL), Endocrinology 144 (2003), 4616-4625.
37. D. Ron and P. Walter, Signal integration in the endoplasmic reticulum unfolded protein response, Nat. Rev. Mol. Cell Biol. 8 (2007), 519-529.
38. R. Schneider-Stock and M. Ocker, Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors, IDrugs 10 (2007), 557-561.
39. M. Schwartz, S. Roayaie and M. Konstadoulakis, Strategies for the management of hepatocellular carcinoma, Nat. Clin. Pract. Oncol. 4 (2007), 424-432.
40. R.P. Sharma, C. Rosen, S. Kartan, A. Guidotti, E. Costa, D.R. Grayson and K. Chase, Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population, Schizophr. Res. 88 (2006), 227-231.
41. I. Svechnikova, O. Ammerpohl and T.J. Ekstrom, p21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells, Biochem. Biophys. Res. Commun. 354 (2007), 466-471.
42. G.S. Wu, The functional interactions between the p53 and MAPK signaling pathways, Cancer Biol. Ther. 3 (2004), 156-161.
43. W.S. Xu, R.B. Parmigiani and P.A. Marks, Histone deacety-lase inhibitors: molecular mechanisms of action, Oncogene 26 (2007), 5541-5552.
44. Q.C. Yang, B.F. Zeng, Z.M. Shi, Y. Dong, Z.M. Jiang, J. Huang, Y.M. Lv, C.X. Yang and Y.W. Liu, Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma, J. Exp. Clin. Cancer Res. 25 (2006), 593-599.
45. C. Yu, B.B. Friday, J.P. Lai, A. McCollum, P. Atadja, L.R. Roberts and A.A. Adjei, Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation, Clin. Cancer Res. 13 (2007), 1140-1148.
46. F. Zhang, R.B. Hamanaka, E. Bobrovnikova-Marjon, J.D. Gor-dan, M.S. Dai, H. Lu, M.C. Simon and J.A. Diehl, Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest, J. Biol. Chem. 281 (2006), 30036-30045.
47. S. Zopf, D. Neureiter, S. Bouralexis, T. Abt, K.B. Glaser, K. Okamoto, M. Ganslmayer, E.G. Hahn, C. Herold and M. Ocker, Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo, Int. J. Oncol. 31 (2007), 1391-1402.